Hunan Jiudian Pharmaceutical Co Ltd
SZSE:300705
Gross Margin
Gross Margin shows how much money a company keeps from each dollar of sales after paying for the products it sells. It tells how profitable the company`s core business is before other expenses.
Gross Margin shows how much money a company keeps from each dollar of sales after paying for the products it sells. It tells how profitable the company`s core business is before other expenses.
Peer Comparison
| Country | Company | Market Cap |
Gross Margin |
||
|---|---|---|---|---|---|
| CN |
|
Hunan Jiudian Pharmaceutical Co Ltd
SZSE:300705
|
7.7B CNY |
Loading...
|
|
| US |
|
Eli Lilly and Co
NYSE:LLY
|
959.3B USD |
Loading...
|
|
| US |
|
Johnson & Johnson
NYSE:JNJ
|
585.3B USD |
Loading...
|
|
| CH |
|
Roche Holding AG
SIX:ROG
|
291.8B CHF |
Loading...
|
|
| UK |
|
AstraZeneca PLC
LSE:AZN
|
238.2B GBP |
Loading...
|
|
| CH |
|
Novartis AG
SIX:NOVN
|
242.2B CHF |
Loading...
|
|
| US |
|
Merck & Co Inc
NYSE:MRK
|
305.1B USD |
Loading...
|
|
| IE |
E
|
Endo International PLC
LSE:0Y5F
|
218B USD |
Loading...
|
|
| DK |
|
Novo Nordisk A/S
CSE:NOVO B
|
1.3T DKK |
Loading...
|
|
| US |
|
Pfizer Inc
NYSE:PFE
|
151.4B USD |
Loading...
|
|
| UK |
|
GSK plc
XETRA:GS71
|
103.6B EUR |
Loading...
|
Market Distribution
| Min | -2 148% |
| 30th Percentile | 14.3% |
| Median | 23% |
| 70th Percentile | 34.6% |
| Max | 775.2% |
Other Profitability Ratios
Hunan Jiudian Pharmaceutical Co Ltd
Glance View
Hunan Jiudian Pharmaceutical Co Ltd, nestled amidst the vibrant commercial landscape of China, exemplifies the dynamic evolution of the pharmaceutical industry within the region. Founded on the principles of innovation and resilience, the company has carved a niche by focusing on the development, production, and sale of a variety of active pharmaceutical ingredients (APIs) and finished dosage formulations. It operates through an intricate web of research and development that is deeply aligned with the latest advancements in medical science. Central to its operations is a robust R&D facility that not only ensures high-standard quality control but also keeps the pipeline brimming with potential new products. This forward-thinking approach is critical, as it continually feeds the market with pharmaceuticals that cater to both chronic and acute health conditions, ranging from anti-infectives to cardiovascular drugs. The company capitalizes on a vertically integrated business model, which substantially aids in controlling cost and quality across all stages of production. By managing a seamless supply chain that extends from raw material procurement to drug distribution, Hunan Jiudian Pharmaceutical ensures both operational efficiency and market competitiveness. Revenue streams largely flow from the sale of its proprietary products in domestic and international markets, supported by a comprehensive marketing strategy and a broad distribution network. This pragmatic blend of science, strategy, and salesmanship allows the company not only to generate profits but also to contribute significantly to the global pharmaceutical framework, marking its presence as a formidable player in this ever-changing industry.
See Also
Gross Margin is calculated by dividing the Gross Profit by the Revenue.
The current Gross Margin for Hunan Jiudian Pharmaceutical Co Ltd is 72.6%, which is below its 3-year median of 74.4%.
Over the last 3 years, Hunan Jiudian Pharmaceutical Co Ltd’s Gross Margin has decreased from 76.9% to 72.6%. During this period, it reached a low of 72.3% on Mar 31, 2025 and a high of 77.5% on Dec 31, 2022.